Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Marie Wislez, Julien Mazières, A. Lavolé, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e005636-e005636
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1672-1684
Open Access | Times Cited: 276
Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer
Jamie E. Chaft, Yu Shyr, Boris Sepesi, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 546-555
Open Access | Times Cited: 157
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Jin U. Kang, Chao Zhang, Wen‐Zhao Zhong
Cancer Communications (2021) Vol. 41, Iss. 4, pp. 287-302
Open Access | Times Cited: 118
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza E.L. Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Tina Cascone, Gozde Kar, Jonathan Spicer, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2394-2411
Open Access | Times Cited: 59
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Giuseppe Luigi Banna, Mohd Ali Hassan, Alessio Signori, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246837-e246837
Open Access | Times Cited: 29
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Wenhua Liang, Kaican Cai, Chun Chen, et al.
Translational Lung Cancer Research (2020) Vol. 9, Iss. 6, pp. 2696-2715
Open Access | Times Cited: 73
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
Boris Sepesi, Nicolas Zhou, William N. William, et al.
Journal of Thoracic and Cardiovascular Surgery (2022) Vol. 164, Iss. 5, pp. 1327-1337
Open Access | Times Cited: 54
Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy
Ajoy Oommen John, Nithya Ramnath
The Oncologist (2023) Vol. 28, Iss. 9, pp. 752-764
Open Access | Times Cited: 27
The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art
François Montagne, Florian Guisier, Nicolas Vénissac, et al.
Cancers (2021) Vol. 13, Iss. 15, pp. 3711-3711
Open Access | Times Cited: 47
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Nasser K. Altorki, Zachary Walsh, Johannes C. Melms, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Emma Boydell, José Luís Sandoval, Olivier Michielin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11849-11849
Open Access | Times Cited: 17
Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint
Paula A. Ugalde, Valérie Lacroix, Paul Van Schil
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 6, pp. 858-861
Closed Access | Times Cited: 7
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
Chiara Lazzari, Calogera Claudia Spagnolo, Giuliana Ciappina, et al.
Current Oncology (2023) Vol. 30, Iss. 4, pp. 3684-3696
Open Access | Times Cited: 16
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, et al.
Journal of Cancer (2023) Vol. 14, Iss. 5, pp. 850-873
Open Access | Times Cited: 16
Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials
Run‐Cong Nie, FoPing Chen, Mariano Provencio, et al.
European Journal of Cancer (2023) Vol. 186, pp. 211-221
Open Access | Times Cited: 15
Neoadjuvant therapy in non-small cell lung cancer
Christopher H. Grant, Garo Hagopian, Misako Nagasaka
Critical Reviews in Oncology/Hematology (2023) Vol. 190, pp. 104080-104080
Open Access | Times Cited: 15
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
A. Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113404-113404
Closed Access | Times Cited: 15
Immunotherapy for early-stage non-small cell lung cancer: A system review
Jingyi Gao, Chao Zhang, Zhigang Wei, et al.
Journal of Cancer Research and Therapeutics (2023) Vol. 19, Iss. 4, pp. 849-865
Open Access | Times Cited: 13
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Guillermo Suay, Juan Carlos García‐Cañaveras, Francisco Aparisi, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4433-4433
Open Access | Times Cited: 13
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
Chun Ho Szeto, Walid Shalata, Alexander Yakobson, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 23, pp. 5614-5614
Open Access | Times Cited: 31
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Michael R. Conroy, Colum Dennehy, Patrick M. Forde
Lung Cancer (2023) Vol. 183, pp. 107314-107314
Closed Access | Times Cited: 11
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
Claudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102845-102845
Closed Access | Times Cited: 4
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Yuzhu Chen, Fei Qi, Chao Sun, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Surgical Techniques for Non-Small-Cell Lung Cancer After Neoadjuvant Chemo-Immunotherapy: State of Art and Review of the Literature
Beatrice Trabalza Marinucci, Massimiliano Mancini, Alessandra Siciliani, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 638-638
Open Access
Page 1 - Next Page

Scroll to top